Search
Results: 20
Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries.
Katy AM Gaythorpe, Kaja Abbas, John Huber, Andromachi Karachaliou, Niket Thakkar, Kim Woodruff, Xiang Li, Susy Echeverria-Londono, VIMC Working Group on COVID-19 Impact on Vaccine Preventable Disease, Matthew Ferrari, Michael L Jackson, Kevin McCarthy, T Alex Perkins, Caroline Trotter, Mark Jit
Sep 13, 2021
BACKGROUND: Childhood immunisation services have been disrupted by the COVID-19 pandemic. WHO recommends considering outbreak risk using epidemiological criteria when deciding whether to conduct preventive vaccination campaigns...
covid-19 EPIDEMIOLOGY Global Health human Mathematical modelling Measles Medicine Meningococcal disease Vaccination Yellow Fever Adolescent Adult Africa Bangladesh covid-19 Child Child Preschool Disease Outbreaks Humans Immunization Programs Infant Measles Measles Vaccine Meningococcal Infections Meningococcal Vaccines Pandemics Risk Assessment SARS-CoV-2 Vaccination Yellow Fever Yellow Fever Vaccine Young Adult
A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.
Olivier Manigart, Caroline Trotter, Helen Findlow, Abraham Assefa, Wude Mihret, Tesfaye Moti Demisse, Biruk Yeshitela, Isaac Osei, Abraham Hodgson, Stephen Laryea Quaye, Samba Sow, Mamadou Coulibaly, Kanny Diallo, Awa Traore, Jean-Marc Collard, Rahamatou Moustapha Boukary, Oumarou Djermakoye, Ali Elhaji Mahamane, Jean-François Jusot, Cheikh Sokhna, Serge Alavo, Souleymane Doucoure, El Hadj Ba, Mariétou Dieng, Aldiouma Diallo, Doumagoum Moto Daugla, Babatunji Omotara, Daniel Chandramohan, Musa Hassan-King, Maria Nascimento, Arouna Woukeu, Ray Borrow, James M Stuart, Brian Greenwood
Feb 15, 2016
Adolescent Adult Africa Aged Antibodies Bacterial Carrier State Child Child Preschool Cross-Sectional Studies Enzyme-Linked Immunosorbent Assay Epidemics Female Humans Immunoglobulin G Immunologic Memory Infant Male Meningitis Meningococcal Meningococcal Vaccines Middle Aged Neisseria meningitidis Seroepidemiologic Studies Serogroup Vaccination
Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia.
Helen S Marshall, Mark McMillan, Ann P Koehler, Andrew Lawrence, Thomas R Sullivan, Jenny M MacLennan, Martin CJ Maiden, Shamez N Ladhani, Mary E Ramsay, Caroline Trotter, Ray Borrow, Adam Finn, Charlene M Kahler, Jane Whelan, Kumaran Vadivelu, Peter Richmond
Feb 27, 2020
BACKGROUND: The meningococcal group B vaccine 4CMenB is a new, recombinant protein-based vaccine that is licensed to protect against invasive group B meningococcal disease. However, its role in preventing transmission and...
B Part of It protocol
Helen S Marshall, Mark McMillan, Ann Koehler, Andrew Lawrence, Jenny M MacLennan, Martin CJ Maiden, Mary Ramsay, Shamez N Ladhani, Caroline Trotter, Ray Borrow, Adam Finn, Thomas Sullivan, Peter Richmond, Charlene M Kahler, Jane Whelan, Kumaran Vadivelu
Sep 05, 2018
INTRODUCTION: South Australia (SA) has the highest notification rate of invasive meningococcal disease in Australia with the majority of cases due to serogroup B. Neisseria meningitidis is carried in the pharynx, with...
Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15
CL Trotter, C Lingani, K Fernandez, LV Cooper, A Bita, C Tevi-Benissan, O Ronveaux, M-P Préziosi, JM Stuart
Aug 08, 2017
BACKGROUND: In preparation for the introduction of MenAfriVac, a meningococcal group A conjugate vaccine developed for the African meningitis belt, an enhanced meningitis surveillance network was established. We analysed...
'Be on the TEAM' Study (Teenagers Against Meningitis)
Jeremy Carr, Emma Plested, Parvinder Aley, Susana Camara, Kimberly Davis, Jenny M MacLennan, Steve Gray, Saul N Faust, Ray Borrow, Hannah Christensen, Caroline Trotter, Martin CJ Maiden, Adam Finn, Matthew D Snape, ‘Be on the TEAM’ investigators
Oct 27, 2020
INTRODUCTION: Capsular group B Neisseria meningitidis (MenB) is the most common cause of invasive meningococcal disease (IMD) in many parts of the world. A MenB vaccine directed against the polysaccharide capsule remains elusive...
Paediatric infectious disease and immunisation paediatric intensive and critical care Infectious Diseases Paediatrics Adolescent Adult Humans Meningitis Meningococcal Infections Meningococcal Vaccines Neisseria meningitidis Neisseria meningitidis Serogroup B Randomized Controlled Trials as Topic State Medicine Vaccination Young Adult
Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger
SM Niaz Arifin, Christoph Zimmer, Caroline Trotter, Anaïs Colombini, Fati Sidikou, F Marc LaForce, Ted Cohen, Reza Yaesoubi
Jun 28, 2019
Structure of a protective epitope reveals the importance of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide.
Pedro Henriques, Lucia Dello Iacono, Ana Gimeno, Alessia Biolchi, Maria Rosaria Romano, Ana Arda, Gonҫalo JL Bernardes, Jesus Jimenez-Barbero, Francesco Berti, Rino Rappuoli, Roberto Adamo
Nov 16, 2020
Meningococcal meningitis remains a substantial cause of mortality and morbidity worldwide. Until recently, countries in the African meningitis belt were susceptible to devastating outbreaks, largely attributed to serogroup A...
Neisseria meningitidis Carbohydrates structural glycobiology vaccines Acetylation Adolescent Antibodies Bacterial Child Clinical Trials Phase II as Topic Crystallography X-Ray Epitopes Female Humans Immunogenicity Vaccine Immunoglobulin Fab Fragments Male Meningitis Meningococcal Meningococcal Vaccines Molecular Docking Simulation Multicenter Studies as Topic Neisseria meningitidis Polysaccharides Bacterial Randomized Controlled Trials as Topic Serogroup Serum Bactericidal Antibody Assay vaccines Conjugate
Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
Hannah Christensen, Tom Irving, Judith Koch, Caroline L Trotter, Bernhard Ultsch, Felix Weidemann, Ole Wichmann, Wiebke Hellenbrand
Apr 21, 2016
The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso
Reza Yaesoubi, Caroline Trotter, Caroline Colijn, Maziar Yaesoubi, Anaïs Colombini, Stephen Resch, Paul A Kristiansen, F Marc LaForce, Ted Cohen
Feb 27, 2018
BACKGROUND: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt. In this context, important questions remain about the performance of...
Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries.
Katy AM Gaythorpe, Kaja Abbas, John Huber, Andromachi Karachaliou, Niket Thakkar, Kim Woodruff, Xiang Li, Susy Echeverria-Londono, Matthew Ferrari, Michael L Jackson, Kevin McCarthy, T Alex Perkins, Caroline Trotter, Mark Jit
Jul 28, 2021
Background
Childhood immunisation services have been disrupted by the COVID-19 pandemic. WHO recommends considering outbreak risk using epidemiological criteria when deciding whether to conduct preventive vaccination...
human Vaccination Medicine EPIDEMIOLOGY Measles Yellow Fever Global Health Meningococcal disease Mathematical modelling covid-19 Humans Meningococcal Infections Meningococcal Vaccines Measles Vaccine Yellow Fever Vaccine Risk Assessment Disease Outbreaks Adolescent Adult Child Child Preschool Infant Immunization Programs Africa Bangladesh Young Adult Pandemics covid-19 SARS-CoV-2
Published by: eLife
Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso
Seydou Yaro, Berthe-Marie Njanpop Lafourcade, Soumeya Ouangraoua, Aline Ouoba, Hervé Kpoda, Helen Findlow, Haoua Tall, Joy Seanehia, Catherine Martin, Jean-Bosco Ouedraogo, Bradford Gessner, Nicolas Meda, Ray Borrow, Caroline Trotter, Judith E Mueller
Sep 08, 2018
Antibody kinetics following vaccination with MenAfriVac
Michael White, Olubukola Idoko, Samba Sow, Aldiouma Diallo, Beate Kampmann, Ray Borrow, Caroline Trotter
Feb 21, 2019
BACKGROUND: A meningococcal group A conjugate vaccine, PsA-TT (also known as MenAfriVac), was developed with the support of the Meningitis Vaccine Project. Around 280 million individuals aged 1-29 years have been immunised...
Adolescent Adult Antibodies Bacterial Antibody Formation Blood Bactericidal Activity Child Child Preschool Enzyme-Linked Immunosorbent Assay Female Gambia Humans Infant Longitudinal Studies Male Mali Meningitis Meningococcal Meningococcal Vaccines Neisseria meningitidis Serogroup A Randomized Controlled Trials as Topic Senegal Time Factors Young Adult
Measurement of antibodies to pneumococcal, meningococcal and haemophilus polysaccharides, and tetanus and diphtheria toxoids using a 19-plexed assay
Alison M E Whitelegg, Jane Birtwistle, Alex Richter, John Campbell, James E Turner, Tarana M Ahmed, Lynda J Giles, Mark Fellows, Tim Plant, Alastair J Ferraro, Mark Cobbold, Mark T Drayson, Calman A MacLennan
Mar 30, 2012
The measurement of antibody responses to vaccination is useful in the assessment of immune status in suspected immune deficiency. Previous reliance on enzyme-linked immunoabsorbent assays (ELISA) has been cumbersome...
Adolescent Adult Aged Diphtheria Toxoid Flow Cytometry Haemophilus Vaccines Humans Immunoglobulin G Immunoglobulin M Meningococcal Vaccines Middle Aged Pneumococcal Vaccines Reproducibility of Results Sensitivity and Specificity Tetanus Toxoid Young Adult /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being name=SDG 3 - Good Health and Well-being
Measurement of antibodies to pneumococcal, meningococcal and haemophilus polysaccharides, and tetanus and diphtheria toxoids using a 19-plexed assay
Alison M E Whitelegg, Jane Birtwistle, Alex Richter, John Campbell, James E Turner, Tarana M Ahmed, Lynda J Giles, Mark Fellows, Tim Plant, Alastair J Ferraro, Mark Cobbold, Mark T Drayson, Calman A MacLennan
Mar 30, 2012
The measurement of antibody responses to vaccination is useful in the assessment of immune status in suspected immune deficiency. Previous reliance on enzyme-linked immunoabsorbent assays (ELISA) has been cumbersome...
Adolescent Adult Aged Diphtheria Toxoid Flow Cytometry Haemophilus Vaccines Humans Immunoglobulin G Immunoglobulin M Meningococcal Vaccines Middle Aged Pneumococcal Vaccines Reproducibility of Results Sensitivity and Specificity Tetanus Toxoid Young Adult /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being name=SDG 3 - Good Health and Well-being
The Global Meningococcal Initiative
Ray Borrow, Pedro Alarcón, Josefina Carlos, Dominique A Caugant, Hannah Christensen, Roberto Debbag, Philippe De Wals, Gabriela Echániz-Aviles, Jamie Findlow, Chris Head, Daphne Holt, Hajime Kamiya, Samir K Saha, Sergey Sidorenko, Muhamed-Kheir Taha, Caroline Trotter, Julio A Vázquez Moreno, Anne von Gottberg, Marco AP Sáfadi, Global Meningococcal Initiative
Jan 31, 2017
EPIDEMIOLOGY Global Meningococcal Initiative MenW Neisseria meningitidis Meningococcal disease outbreaks Prevention serogroups SURVEILLANCE Vaccination Disease Outbreaks Global Health Humans Immunization Programs Incidence Meningitis Meningococcal Meningococcal Infections Meningococcal Vaccines Neisseria meningitidis vaccines Conjugate
Knowledge, beliefs and practices regarding prevention of bacterial meningitis in Burkina Faso, 5 years after MenAfriVac mass campaigns.
Judith E Mueller, Joy Seanehia, Seydou Yaro, Caroline L Trotter, Ray Borrow, Tamara Giles-Vernick
Aug 20, 2021
BACKGROUND: To adapt communications concerning vaccine prevention, we studied knowledge, beliefs and practices around meningitis risk and prevention in a young adult population in Burkina Faso in 2016, 5 years after the...
Meningococcal carriage in the African meningitis belt.
MenAfriCar consortium
Jan 23, 2018
A meningococcal serogroup A polysaccharide/tetanus toxoid conjugate vaccine (PsA-TT) (MenAfriVac(™) ) is being deployed in countries of the African meningitis belt. Experience with other polysaccharide/protein conjugate vaccines...
Africa MenAfriCar Neisseria meningitidis meningococcal carriage Meningococcal Vaccines meningococcus Adolescent Adult Africa Carrier State Child Child Preschool Cross-Sectional Studies Enzyme-Linked Immunosorbent Assay Epidemics Humans Immunization Programs Infant International Cooperation Meningitis Meningococcal Meningococcal Vaccines Neisseria meningitidis Serogroup A Pharynx Pilot Projects Polymerase Chain Reaction Program Evaluation Specimen Handling vaccines Conjugate Young Adult
Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt.
Africa mathematical modeling Meningitis vaccine Adolescent Adult Africa Age Factors Aged Aged 80 and over Child Child Preschool Disease Transmission Infectious Female Humans Infant Infant Newborn Male Meningitis Meningococcal Meningococcal Vaccines Middle Aged Models Theoretical Seasons Vaccination Young Adult
The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.
MenAfriCar consortium
Jun 02, 2015
Africa Neisseria meningitidis carriage Meningitis meningococcus Adolescent Adult Africa South of the Sahara Carrier State Child Child Preschool Cross-Sectional Studies Female genetic variation Genotype Geography Humans Infant Male Mass Vaccination Meningitis Meningococcal Meningococcal Vaccines Neisseria meningitidis prevalence Young Adult